Radiomic signature accurately predicts the risk of metastatic dissemination in late-stage non-small cell lung cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and the median overall survival (OS) is approximately 2-3 years among patients with stage III disease. Furthermore, it is one of the deadliest types of cancer globally due to non-specific symptoms and the lack of a biomarker for early detection. The most important decision that clinicians need to make after a lung cancer diagnosis is the selection of a treatment schedule. This decision is based on, among others factors, the risk of developing metastasis.

Methods

A cohort of 115 NSCLC patients treated using chemotherapy and radiotherapy (RT) with curative intent was retrospectively collated and included patients for whom positron emission tomography/computed tomography (PET/CT) images, acqui

SUBMITTER: Wilk AM 

PROVIDER: S-EPMC10413035 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature